Skip to main content
Premium Trial:

Request an Annual Quote

Eremid Genomic Services Receives CLIA Accreditation for New Lab

NEW YORK – Eremid Genomic Services said on Tuesday that it has received CLIA accreditation for its new clinical laboratory.

The Kannapolis, North Carolina-based lab will serve clinical and direct-to-consumer clients with genomic analysis.

"Our new cutting-edge lab brings with it a host of new possibilities for our customers. We are excited to now partner with clinical researchers and commercial enterprises to develop and offer a range of genomics-based assays for clinical samples," Julian Curaba, Eremid's CSO, said in a statement.

Eremid, a contract research organization spun out of the David H. Murdock Research Institute and formerly called Eremid Research Services, was acquired by venture firm Coddle Creek Capital in September. Financial details were not disclosed but the firms said that CCC made a multimillion-dollar investment in Eremid.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.